Baricitinib plus Remdesivir shows promise for treating COVID-19
E-Mail IMAGE: This colorized transmission electron micrograph shows a SARS-CoV-2 virus particle, isolated from a patient. view more Credit: NIAID WHAT: The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), p...
United States Elizabeth Deatrick Eli Lilly National Cancer Institute National Institute Of Allergy Us Department Of Health
Source: eurekalert.org